EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

Lu-Ning Sun, Yang Zhao, Zhou-Yi Qian, Xiang-Long Chen, Hong Ma, Yu-Jiao Guo, Hao Shen, Yong-Qing Wang iD

Molecules · 2023

DOI: 10.3390/molecules28031205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Lu-Ning Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: First Affiliated Hospital of Nanjing Medical University, Center for Healthy Development Research of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib, zanubrutinib, ibrutinib, and its active metabolite dihydrodiol ibrutinib in human plasma. The Ibrutinib-d5 was used as the internal standard. Pretreatment was performed using a simple protein precipitation step using acetonitrile. The ACQUITY UPLC HSS T3 column (2.1×50 mm, 1.8 μm) was used to separate the analytes, and the run time was 6.5 min. The mobile phase consisted of acetonitrile and 10 mM of ammonium formate, which contained 0.1% formic acid. The multiple reactions’ monitoring transitions were selected at m/z 428.1→411.2, 472.2→455.2, 441.1→304.2, 475.2→304.2 and 446.2→309.2 respectively for orelabrutinib, zanubrutinib, ibrutinib, dihydrodiol ibrutinib and ibrutinib-d5 using positive ion electrospray ionization. The standard curves were linear, from 0.400 to 200 ng/mL for ibrutinib and dihydrodiol ibrutinib, 1.00–500 ng/mL for orelabrutinib, and 2.00–1000 ng/mL for zanubrutinib. Selectivity, the lower limit of quantitation, precision, accuracy, matrix effect, recovery, stability, and dilution integrity all met the acceptance criteria of FDA guidance. This method was used to quantify the plasma levels of orelabrutinib, zanubrutinib, ibrutinib, and dihydrodiol ibrutinib in clinical patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryProtein Kinase InhibitorsHumansChromatography, LiquidChromatography, High Pressure LiquidReproducibility of ResultsAcetonitrilesAdeninePiperidinesNaphthalenesPyrazolesPyrimidines

Stichwörter der Autor:innen

Bruton’s tyrosine kinase inhibitorLC-MS/MShuman plasma

Substanzen

Protein Kinase InhibitorsAcetonitrilesibrutinibAdeninePiperidinestrans-1,2-dihydro-1,2-naphthalenediolNaphthaleneszanubrutinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

ORCID-Profile: Yong-Qing Wang

Förderung

  • First Affiliated Hospital of Nanjing Medical University
  • Center for Healthy Development Research of Jiangsu Province

Zitieren

APA

Sun, L. N., Zhao, Y., Qian, Z. Y., Chen, X. L., Ma, H., Guo, Y. J., Shen, H., & Wang, Y. Q. (2023). Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS. Molecules. https://doi.org/10.3390/molecules28031205

Vancouver

Sun LN, Zhao Y, Qian ZY, Chen XL, Ma H, Guo YJ, et al. Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS. Molecules. 2023. doi:10.3390/molecules28031205

BibTeX
@article{Sun2023,
  author = {Sun, Lu-Ning and Zhao, Yang and Qian, Zhou-Yi and Chen, Xiang-Long and Ma, Hong and Guo, Yu-Jiao and Shen, Hao and Wang, Yong-Qing},
  title = {Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28031205}
}
Kostenlos starten →